NET degradation represents a safe treatment option as drugs like DNase I are already used in other diseases such as cystic fibrosis and off-label use for COVID-19.42,43 Furthermore, heparin or colchicine administration presents options to interfere with NET formation by inhibiting histone-induced coagulation or actin cytoskeleton remodeling in NET-forming neutrophils, respectively.44,45 Lastly, novel inhibitors interfering with MPO or PAD4 represent potential therapeutic drugs. This evidence concerns the gene MPO and COVID-19.